As used in this Annual Report, “we,” “us” and “our” refer to Helix BioMedix Inc. We are a biopharmaceutical company with an extensive proprietary library of structurally diverse bioactive peptides and patents covering hundreds of thousands of peptide sequences. Our mission is to enrich clinical practice and the patient/consumer experience by developing and commercializing topically applied products which offer the benefits of our advanced bioactive small molecule peptide technology. Our vision is to be recognized as the world leader in the identification, qualification and commercialization of natural and synthetic peptides.
Company profile
Ticker
HXBM
Exchange
CEO
Robin L. Carmichael
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CARTEL ACQUISITIONS INC, CARIBBEAN ACQUISTIONS INC
SEC CIK
Corporate docs
IRS number
912099117
HXBM stock data
Latest filings (excl ownership)
CT ORDER
Confidential treatment order
26 Dec 19
D
$5.63M in debt / options / securities to be acquired, sold $5.63M, 1 investor
30 Jul 19
CT ORDER
Confidential treatment order
5 Feb 18
CT ORDER
Confidential treatment order
3 Oct 17
CT ORDER
Confidential treatment order
29 Jan 15
D
$4.5M in debt / options / securities to be acquired, sold $1M, 1 investor
3 Dec 14
CT ORDER
Confidential treatment order
12 Feb 14
CT ORDER
Confidential treatment order
17 Jul 13
CT ORDER
Confidential treatment order
1 Jul 13
D
$4.5M in equity / options / securities to be acquired, sold $500K, 1 investor
1 May 13
Latest ownership filings
No filings